Agilent and FDA collaborate over salmonella
Agilent (Santa Clara, California, USA) has announced that it has entered into a Cooperative Research and Development Agreement with the US Food and Drug Administration (FDA) to develop new tools to detect and analyse pathogens in food.
Agilent (Santa Clara, California, USA) has announced that it has entered into a Cooperative Research and Development Agreement with the US Food and Drug Administration (FDA) to develop new tools to detect and analyse pathogens in food.
Salmonella, in particular, is being focused on and the goal is to develop a novel assay panel to identify subtypes of salmonella in food using mass spectrometry.
Eric W. Brown, PhD, director, division of microbiology, FDA, said, “This effort on the part of Agilent is of extraordinary importance to the FDA. We expect this collaboration will be an important step in the development of new and specific tools for tracking bacterial pathogens in foods.”
The collaboration is also seeking to improve DNA-based tools for confirming that seafood is correctly labelled by detecting such things as intentional mislabelling to avoid tariffs and import restrictions, or economic fraud where a less expensive species of fish is sold as a more expensive one.
Paul Zavitsanos, Agilent global food safety manager, commented, “We’re very pleased to be collaborating with the FDA because this work holds tremendous potential for solving some very challenging threats to the safety and integrity of the food supply.”
For more information please visit ref="http://www.agilent.com">www.agilent.com
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
